Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 2Phase 2/3 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Stomach Neoplasms 11Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Neoplasm Metastasis 3Small Cell Lung Carcinoma 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Diseases 1Progression Free Survival 1PD-L1 Positive Non-small Cell Lung Cancer 1Lung Neoplasms 1HR+/HER2-breast Cancer 1Gastrointestinal Neoplasms 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1Carcinoma, Ovarian Epithelial 1Apatinib 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × apatinib × Clear all
NCT07371910 2026-01-28

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Active not recruiting
200 enrolled
Breast

Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
80 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡